Valuation
- Market cap
- 222,677,000
- Revenue TTM
- $2,800,000
- Net income TTM
- $-130,300,000
- PE ratio
- 0.00
- Forward PE
- —
- Profit margin
- -4,653.57%
- Debt to equity
- 0.00
Trading
- Volume
- 200,300
- Avg volume
- 127,870
- Day's range
- $7.29 – $8.05
- Shares out
- 30,255,000
- Stochastic %K
- 27%
- Beta
- 0.65
- Analysts
- Strong Sell
- Price target
- $33.67
Company profile
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasth...
Show more
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, provides mRNA cell therapies for the treatment of autoimmune diseases. The company's lead product candidate is Descartes-08, an autologous mRNA chimeric antigen receptor T-cell cell therapy (CAR-T) directed against the B cell maturation antigen (BCMA), which is in Phase 2b clinical trials for the treatment of autoimmune diseases, generalized myasthenia gravis, and systemic lupus erythematosus, as well as rare pediatric disease designation for the treatment of juvenile dermatomyositis. It is also developing Descartes-15, which is in phase 1 trials, an autologous autologous B cell maturation antigen (BCMA) directed mRNA CAR-T to treat patients with multiple myeloma. The company is headquartered in Frederick, Maryland.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 301 348 8698
- Website
- https://www.cartesiantherapeutics.com
- Address
- 7495 New Horizon Way, Frederick, United States
Latest news
No headlines yet.
